Clinical Trial Update: A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. [Phase 3]

View source ↗

Summary

This Phase 3 study evaluates re-treatment with Rituximab (MabThera) in patients with rheumatoid arthritis who had an inadequate response to a single anti-TNF in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2014-09-10